Cellular Senescence and COVID-19 Long-Hauler Syndrome

Overview

About this study

The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria - Longhaulers Cohort:

Subject population: 100 men and women who have been diagnosed with Post-COVID syndrome.

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject or LAR to read and speak the English language.
  • Positive PCR or antibody test within 18 months of initial study visit.
  • Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome.

Exclusion Criteria:

  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject’s risk by participating in the study.
  • Patient is unfit to participate at the discretion of the Principal Investigator.

Inclusion Criteria - Control Cohort:

Subject population: 50 men and women who have not had a known case of COVID or Longhauler’s syndrome.

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject or LAR to read and speak the English language.

Exclusion Criteria:

  • Known case of COVID-19.
  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject’s risk by participating in the study.
  • Patient is unfit to participate at the discretion of the Principal Investigator.

Inclusion Criteria - COVID-19 Control Cohort:

Subject population: 50 men and women who have had a known case of COVID, but not Longhauler’s syndrome.

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject to read and speak the English language.
  • Known case of COVID-19.

Exclusion Criteria:

  • Known Longhauler’s syndrome/Post-COVID
  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject’s risk by participating in the study.

Eligibility last updated 11/19/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

James Kirkland, M.D., Ph.D.

Open for enrollment

Contact information:

Tamara Evans

(507) 284-1004

Evans.Tamara@mayo.edu

More information

Publications

Publications are currently not available